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Abstract
Purpose The first purpose of this study was to determine
the incidence of postoperative nausea and/or vomiting
(PONV) 0–48 h after anesthesia at a Japanese cancer
center. The second purpose of this study was to collect
information on PONV risk factors, independently, in the
categories of patient-related, anesthesia-related, and sur-
gery-related factors.
Methods The frequency of nausea and vomiting was
prospectively investigated from 0 to 48 h after anesthesia
in 1645 patients (11–94 years of age) at a single medical
institution. The occurrence of nausea and vomiting and the
use of antiemetics were recorded up to 48 h after anesthesia.
Patient-related, anesthesia-related, and surgery-related fac-
tors were also recorded and submitted to multiple logistic
regression analysis to determine the relationship of these
factors to nausea and vomiting.
Results The incidences of nausea and vomiting from 0 to
24 h after anesthesia were 40 and 22 %, respectively. The
incidences 24–48 h after anesthesia were 10 and 3 %,
respectively. Female sex, previous history of PONV, pro-
longed anesthesia, and remifentanil use during surgery
were identified as risk factors for both nausea and
vomiting. The use of a volatile anesthetic, use of fentanyl
during surgery, postoperative use of opioids, nonsmoking
status, and drinking alcohol on 4 or fewer days per week
were identified as risk factors for nausea alone.
Conclusion The incidence of and risk factors for PONV
at a Japanese cancer center according to this study are
comparable to those reported elsewhere.
Keywords Postoperative nausea and vomiting  PONV 
Prospective study  Risk factors  Japan
Introduction
Postoperative nausea and/or vomiting (PONV) is a signif-
icant postoperative complication that has been repeatedly
investigated in surveys of incidence [1–4]. Many studies
have sought to determine risk factors for PONV [1, 3, 5, 6].
Numerous antiemetics have been developed [7–11] and are
used for PONV as recommended in various guidelines
[12–14]. However, antiemetics such as 5-HT3 receptor
antagonists, dexamethasone, and neurokinin-1 (NK1)
receptor antagonists are still unapproved for use in Japan.
This leaves metoclopramide as the only therapeutic option
and deprives Japanese physicians of effective therapies for
PONV. The unavailability of new antiemetics is partially
attributable to a lack of large-scale studies to investigate
the incidence of PONV in this country. Conclusive evi-
dence that PONV is a significant concern in Japan with an
incidence essentially no different from that in other coun-
tries would substantiate the approval of the new antie-
metics, a class of agents widely used elsewhere, for use in
Japan.
The first purpose of this study was to determine the
incidence of PONV 0–48 h after anesthesia at a Japanese
Data from this study were presented in part at The 59th Annual
Meeting of the Japanese Society of Anesthesiologists, 2012, Kobe.
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cancer center. The second purpose of this study was to
collect information on PONV risk factors, independently,
in the categories of patient-related, anesthesia-related, and
surgery-related factors.
Subjects, materials, and methods
This study was designed as a prospective cohort study to
analyze the incidence of PONV and risk factors for PONV.
Following internal ethics committee approval, the study
was conducted at a single center from June 15 to Sep-
tember 30, 2010.
Subjects
The subjects of the study were patients with an American
Society of Anesthesiologists physical status (ASA PS) of I to
III who underwent elective surgery with general or local
anesthesia. The following patients were excluded: pregnant
women, patients requiring intensive care unit treatment,
patients receiving or scheduled to receive a mild or greater
emetogenic anticancer drug from 6 days before study entry to
48 h after anesthesia, patients with a symptomatic brain
metastasis, patients unable to communicate for a mental rea-
son, and patients for whom any of the following antiemetics
were used 48 or fewer hours before the start of anesthesia or
during anesthesia: a 5-HT3 receptor antagonist, dexametha-
sone, phenothiazine drug product, butyrophenone drug
product, benzamide drug product, dopamine receptor antag-
onist, antihistamine, or a NK1 receptor antagonist. Patients for
whom none of the exclusion criteria applied and who provided
informed consent in writing were included in the study.
Anesthesia and postoperatively used drugs
No preanesthetic premedication drug was administered.
Propofol was administered to induce anesthesia; rocuroni-
um or vecuronium was administered as a muscle relaxant;
remifentanil, fentanyl, or morphine hydrochloride was
administered as an opioid; sevoflurane, propofol, or nitrous
oxide was administered for maintenance of anesthesia; and
sugammadex sodium or neostigmine was administered to
reverse the muscle relaxants. The attending anesthesiolo-
gist selected the particular drugs as normal. The prophy-
lactic administration of antiemetics was not allowed except
for postoperative rescue. Metoclopramide, which is
approved in Japan for PONV, was used as the antiemetic.
Collecting patient data
The attending anesthesiologist recorded patient character-
istics on the day before surgery. During anesthesia, the
anesthesiologist recorded the disease name, surgery type,
anesthesia used, type and dose of any anesthesia-related
drugs used, and duration of anesthesia. Following anes-
thesia, a ward nurse recorded the antiemetic used.
Evaluating nausea and vomiting
We determined that evaluating PONV until 48 h after
anesthesia could provide data that would be useful in the
future, because NK1 receptor antagonists, the 5-HT3
receptor antagonist palonosetron, and other long-acting
drugs have recently been used for treating PONV. PONV
was therefore evaluated from 0 to 2, 2 to 24, and 24 to 48 h
after anesthesia. PONV was evaluated by an anesthesiol-
ogist in the operating room and a nurse in the wards. The
evaluator recorded whether nausea was present, and if so,
the severity and the number of vomiting or retching epi-
sodes. Nausea was defined as a subjective sensation of the
desire to vomit by the patient without actual movement of
the expelling muscles.
Statistical analysis
The frequencies and percentages of the patient character-
istics were calculated in each category, as follows. The
median age and age range (minimum–maximum) were
calculated along with the mean body weight and standard
deviation. The mean opioid dose was calculated along with
the standard deviation. For the duration of anesthesia, the
lower quartile, median, and upper quartile were calculated.
Next, the frequencies and percentages of subjects with
nausea, vomiting, and PONV were calculated individually
for each surgery type and risk factor at 0–2 h, 2–24 h,
24–48 h, 0–24 h overall, and 0–48 h overall after anes-
thesia. Logistic univariate regression analysis 0–2 h,
2–24 h, 24–48 h, 0–24 h overall, and 0–48 h overall after
anesthesia was conducted to investigate the relationship of
the risk factors to nausea, vomiting, and PONV frequency.
The regression coefficients, standard errors, odds ratios
(ORs), and 95 % confidence intervals (CIs) were calculated
along with Wald P values. To avoid the problems of
multicollinearity between individual risk factors, the sig-
nificance of correlations was tested using Spearman’s
correlation coefficient, and r values of C0.6 were defined
as the presence of association. The 13 factors that had no
multicollinearity issues and that were considered relevant
to PONV were selected from the factors that univariate
analysis suggested as being related and were submitted to
logistic multivariate regression analysis by the forced-entry
method. Adjusted ORs, 95 % CIs, and Wald P values were
calculated. Seven of these 13 factors (sex, history of
PONV, nonsmoking status, volatile anesthesia vs. total
intravenous anesthesia [TIVA], nitrous oxide, reversal of
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muscle relaxation, and postoperative opioids) were
dichotomous. Because the 13 factors did not include local
anesthesia, multivariate analysis was performed after
excluding the cases of local anesthesia. Remifentanil and
fentanyl doses were analyzed as continuous variables, with
adjusted ORs calculated every 1000 lg for remifentanil
and every 100 lg for fentanyl. The category variables for
the remaining 4 factors were as follows. For body mass
index (BMI), C25 kg/m2 and \25 kg/m2, for duration of
anesthesia, [1 h and B1 h, for alcohol drinking, on
B4 days per week and [4 days per week, and for age,
C50 years and\50 years. In all analyses a P value of less
than 0.05 constituted statistical significance. SAS 9.2 (SAS
Institute, Cary, NC, USA) was used to perform the statis-
tical analyses.
Results
All 1645 patients undergoing surgery who did not satisfy
any of the exclusion criteria were included in the study.
The breakdowns for the surgery types were as follows:
gynecological surgery (GYN) 273 (17 %), breast surgery
399 (24 %), orthopedic surgery (ORT) 136 (8 %), respi-
ratory surgery (RES) 100 (6 %), abdominal surgery (ABD)
599 (36 %), and otological surgery (OTO) 138 (8 %).
Patient baseline characteristics are shown in (Table 1).
A total of 1608 patients (98 %) underwent general anes-
thesia, and 37 patients (2 %) underwent spinal anesthesia.
The duration of anesthesia was 204 min (131–290 min)
[median (quartile 1–quartile 3)]. Anesthesia type, drugs
used, and postoperative analgesia are presented in detail in
Table 2. The median fentanyl dose was 150 lg and the
median remifentanil dose was 1500 lg. As postoperative
analgesia, an epidural local anesthetic was used in 137
patients (8 %), an epidural opioid was used in 604 patients
(37 %), fentanyl intravenous patient-controlled analgesia
(IVPCA) was used in 83 patients (5 %), a nonsteroidal
anti-inflammatory drug (NSAID) was used in 485 patients
(29 %), and additional intravenous opioids (pentazocine or
morphine) were used in 125 patients (8 %).
The incidences of nausea, vomiting, and PONV and the
usage of antiemetics are shown in Table 3 according to sex,
type of anesthesia, and the type of surgery. The incidences
of nausea and vomiting from 0 to 24 h after anesthesia
were 40 and 22 %, respectively. Twenty-four percent of
the patients used an antiemetic. The incidences of nausea
and vomiting from 24 to 48 h after anesthesia were 10 and
3 %, respectively. The incidences of nausea and vomiting
Table 1 Patient characteristics
Characteristic
Sex
Female n (%) 1051 (63.9)
Male n (%) 594 (36.1)
Age (years) median (range) 59 (11–94)
-29 n (%) 71 (4.3)
30–39 n (%) 154 (9.4)
40–49 n (%) 320 (19.5)
50–59 n (%) 303 (18.4)
60–69 n (%) 450 (27.4)
70– n (%) 347 (21.1)
Weight (kg) mean (SD) 57.4 (11.0)
BMI (kg/m2) mean (SD) 22.3 (3.4)
Nonsmoking status n (%) 1438 (87.4)
Drinking (on B4 days per week) 1265 (76.9)
History of PONV n (%) 135 (8.2)
History of motion sickness n (%) 454 (27.6)
ASA PS
I n (%) 752 (45.7)
II n (%) 881 (53.6)
III n (%) 12 (0.7)
ASA PS American Society of Anesthesiologists physical status, BMI
body mass index, PONV postoperative nausea and/or vomiting
Table 2 Perioperative drugs
Drug n (%) Median ± SD
General anesthesia (n = 1608)
Induction
Propofol 1608 (100)
Anesthetic maintenance and reversal
TIVA (propofol) 294 (18.3)
Volatile anesthetic 1314 (81.7)
With nitrous oxide 212 (13.2)
Without nitrous oxide 1102 (68.5)
With epidural anesthesia 743 (46.2)
Muscle relaxant use 1563 (97.2)
Muscle relaxants reversal use 1128 (70.1)
Neostigmine 172 (15.2)
Sugammadex 956 (84.8)
Fentanyl (lg) 1482 (90.1) 150.0 ± 166.8
Remifentanil (lg) 1241 (75.4) 1500.0 ± 1867.1
Morphine (mg) 12 (0.73) 3.0 ± 2.2
48-h Postoperative analgesics
Epidural local anesthetic 137 (8.3)
Opioidsa 709 (43.1)
NSAIDs 485 (29.5)
TIVA total intravenous anesthesia, NSAIDs nonsteroidal anti-inflam-
matory drugs
a Opioids include epidural opioids, fentanyl intravenous patient-
controlled analgesia, and additional intravenous opioids (morphine,
pentazocine)
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over the entire period studied were higher in the female
patients. The incidences of nausea and vomiting after local
anesthesia tended to be lower than those after general
anesthesia, although there were far fewer cases of local
anesthesia as compared with general anesthesia. The inci-
dence of PONV from 0 to 48 h after anesthesia was 52 %
for GYN, 53 % for BRE, and 46 % for OTO. These figures
were higher than the 32 % for ORT, 30 % for RES, and
35 % for ABD. The incidence of PONV from 24 to 48 h
after anesthesia was 19 % for GYN, 13 % for RES, and
12 % for ABD, values which were higher than the 3.3 %
for BRE, 5.9 % for ORT, and 3.5 % for OTO.
The adjusted ORs and CIs of the risk factors for nausea
and vomiting 0–48 h after anesthesia are shown in Table 4.
Patient-related risk factors for both nausea and vomiting
were female sex and history of PONV. Female sex was a
particularly strong risk factor, with adjusted ORs (CIs) of
4.1 (3.00–5.62) and 3.65 (2.52–5.30), respectively. Non-
smoking status and drinking alcohol on 4 or fewer days per
week were identified as risk factors for nausea alone.
Anesthesia-related risk factors for both nausea and vomit-
ing were duration of anesthesia exceeding 1 h and the
intraoperative use of remifentanil. The use of a volatile
anesthetic (versus propofol), the intraoperative use of
fentanyl, and the postoperative use of opioids were iden-
tified as risk factors for nausea alone. The results did not
show age, BMI, nitrous oxide use, or muscle relaxant
antagonists to be correlated with nausea or vomiting.
The strengths of the PONV risk factors at 0–2 h, 2–24 h,
and 24–48 h after anesthesia are shown in Fig. 1. The use of a
volatile anesthesic was highly significant, with an adjusted OR
(CI) of 3.45 (2.22–5.26) from 0 to 2 h after anesthesia, but this
factor was unrelated to PONV 2–24 h and 24–48 h after
anesthesia (P = 0.40, P = 0.73). The use of remifentanil (in
1500 lg increments) was significant, with an adjusted OR
(CI) of 1.65 (1.34–2.03) 0–2 h after anesthesia, but its sig-
nificance decreased to an adjusted OR (CI) of 1.27 (1.06–1.53)
2–24 h after anesthesia and it was insignificant 24–48 h after
anesthesia (P = 0.79). The use of fentanyl (in 150 lg incre-
ments) was significant, with adjusted ORs (CIs) of 1.28
Table 3 Frequencies of PONV and antiemetic administration in the various periods
Outcome Sex Type of anesthesia Type of surgery Total
(n = 1645)
Male
(n = 594)
Female
(n = 1051)
GA
(n = 1608)
RA
(n = 37)
GYN
(n = 273)
BRE
(n = 399)
ORT
(n = 136)
OTO
(n = 138)
RES
(n = 100)
ABD
(n = 599)
0–2 h
Nausea 10.6 30.1 23.5 8.1 32.6 29.1 14.0 26.2 12.0 17.7 23.0
Vomiting 4.4 12.2 9.6 0.0 11.7 10.8 5.1 14.2 3.0 8.2 9.4
PONV 10.6 30.3 23.7 8.1 32.6 29.1 14.0 27.0 12.0 17.9 23.2
Antiemetics 4.5 15.7 12.0 0.0 19.4 14.5 5.1 17.0 1.0 8.2 11.7
2–24 h
Nausea 16.7 40.1 32.4 5.4 35.5 42.1 25.0 31.9 24.0 25.4 31.6
Vomiting 8.4 21.8 17.3 5.4 15.8 23.3 12.5 18.4 15.0 14.2 17.0
PONV 16.7 40.2 32.5 5.4 35.5 42.1 25.0 31.9 24.0 25.7 31.7
Antiemetics 5.4 22.6 16.8 2.7 20.1 24.6 11.8 17.7 8.0 11.4 16.4
24–48 h
Nausea 6.1 11.8 9.9 2.7 18.7 3.3 5.9 3.5 13.0 11.7 9.7
Vomiting 1.5 3.5 2.8 2.7 6.6 0.8 0.7 1.4 3.0 3.2 2.8
PONV 6.1 12.1 10.1 2.7 19.4 3.3 5.9 3.5 13.0 11.9 9.9
Antiemetics 2.2 5.7 4.6 0.0 8.8 0.8 3.7 2.8 3.0 5.7 4.4
0–24 overall
Nausea 21.7 51.0 41.4 10.8 48.4 52.9 31.6 45.4 28.0 31.2 40.4
Vomiting 10.9 28.4 22.6 5.4 23.1 28.3 16.9 26.2 19.0 18.0 22.1
PONV 21.7 51.3 41.6 10.8 48.4 52.9 31.6 45.4 28.0 31.7 40.6
Antiemetics 9.3 32.0 24.4 2.7 31.9 33.8 16.9 28.4 8.0 16.4 23.8
0–48 overall
Nausea 24.1 52.6 43.3 10.8 52.0 52.9 31.6 46.1 30.0 34.2 42.3
Vomiting 11.6 29.1 23.3 5.4 24.2 28.6 16.9 27.0 20.0 19.0 22.8
PONV 24.1 53.0 43.6 10.8 52.4 52.9 31.6 46.1 30.0 34.7 42.6
Antiemetics 10.6 33.5 25.9 2.7 34.4 34.1 19.1 29.1 10.0 18.0 25.2
GA general anesthesia, RA regional anesthesia, GYN gynecological surgery, BRE breast surgery, ORT orthopedic surgery, RES respiratory surgery,
ABD abdominal surgery, OTO otological surgery, PONV postoperative nausea and/or vomiting
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(1.00–1.63) 0–2 h after anesthesia and 1.23 (0.99–1.54)
2–24 h after anesthesia, but it was insignificant 24–48 h after
anesthesia (P = 0.93). The postoperative use of opioids
was insignificant 0–2 h after anesthesia (P = 0.33), but
was highly significant, with adjusted ORs (CIs) of 1.43
(1.08–1.90) 2–24 h after anesthesia and 9.42 (5.50–16.16)
24–48 h after anesthesia. The effects of female sex and history
of PONV, which were risk factors for both nausea and
vomiting, were consistent across the time periods studied.
Discussion
This large-scale study, which was conducted to identify
PONV incidence and risk factors, is the first such study to
demonstrate the high incidence of PONV in Japan. The
study also showed delayed incidencesm from 24 to 48 h
after anesthesiam to be relatively high, at 10 % for nausea
and 3 % for vomiting.
When interpreting the incidences of PONV in the
present study, it must be remembered that the median
duration of anesthesia was 204 min, which was longer than
that in other studies [1–4]. Furthermore, comparing inci-
dences of PONV among studies may not be feasible
because of the difficulty involved with matching patient-,
anesthesia-, and surgery-related factors. We believe that
another study of PONV incidences in Japan, with matched
risk factors is necessary.
Table 4 Adjusted odds ratios of risk factors for nausea and vomiting
within the 0–48 h overall period
Factor Odds
ratio
95 % CI P value
Lower Upper
Nausea (0–48 h)
Sex (female) 4.10 3.00 5.62 \0.0001
Age (C50 years) 0.87 0.65 1.16 0.3407
History of PONV 2.04 1.29 3.23 0.0022
Nonsmoking status 1.56 1.05 2.33 0.0256
BMI (kg/m2) (C25) 1.08 0.79 1.48 0.6394
Drinking (on B4 days per
week)
1.39 1.02 1.92 0.0374
Duration of anesthesia ([1 h) 2.97 1.87 4.71 \0.0001
Volatile anesthesia vs. TIVA 1.61 1.14 2.22 0.0066
Nitrous oxide 1.19 0.74 1.92 0.4641
Remifentanil (per 1000 lg) 1.23 1.11 1.36 \0.0001
Fentanyl (per 100 lg) 1.17 1.04 1.33 0.0103
Reversal of muscle relaxation 1.29 0.97 1.73 0.0849
Postoperative opioids 1.38 1.03 1.83 0.0284
Vomiting (0–48 h)
Sex (female) 3.65 2.52 5.30 \0.0001
Age (C50 years) 1.48 1.06 2.06 0.0214
History of PONV 1.87 1.20 2.91 0.0056
Nonsmoking status 1.27 0.79 2.00 0.3177
BMI (kg/m2) (C25) 0.81 0.57 1.16 0.2531
Drinking (on B4 days per
week)
1.39 0.95 2.04 0.0905
Duration of anesthesia ([1 h) 1.77 1.02 3.06 0.0426
Volatile anesthesia vs. TIVA 1.16 0.81 1.69 0.4180
Nitrous oxide 1.02 0.59 1.75 0.9400
Remifentanil (per 1000 lg) 1.28 1.16 1.41 \0.0001
Fentanyl (per 100 lg) 1.09 0.96 1.23 0.1917
Reversal of muscle relaxation 1.25 0.89 1.74 0.1921
Postoperative opioids 1.21 0.89 1.65 0.2286
CI confidence interval, PONV postoperative nausea and/or vomiting,
BMI body mass index, TIVA total intravenous anesthesia
Fig. 1 Strengths of PONV risk factors at 0–2, 2–24, and 24–48 h
after anesthesia. Note that the x axis is log-scale. PONV postoperative
nausea and/or vomiting, CI confidence interval, drinking B4 per week
drinking on B4 days per week, duration duration of anesthesia,
volatile volatile anesthetic, TIVA total intravenous anesthesia
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PONV incidence is known to be high for certain types of
surgeries [2, 15, 16]. The present study showed a high
incidence of PONV for GYN, BRE, and OTO. It should be
noted that most or all of the patients undergoing these types
of surgeries were female. Some investigators claim that the
relationship between surgery type and PONV is open to
interpretation because patient characteristics and anesthe-
sia-related factors are at play [1, 5, 17, 18]; accordingly, the
effect of surgery type was excluded from multivariate
regression analysis in the present study.
In the present study, female sex and a history of PONV
were identified as risk factors for both nausea and vomit-
ing. Female sex and a history of PONV have previously
been identified as important PONV risk factors [2–4, 18].
We also showed that nonsmoking status and drinking
alcohol on 4 or fewer days per week were risk factors for
nausea alone. Nonsmoking status has previously been
shown to increase PONV incidence [19, 20]. Sweeney [20]
states that higher levels of drinking may suppress PONV.
Our findings validate this prediction.
ASA PS and BMI are reported to affect PONV [2, 3,
21], but these factors were not found to be related to PONV
in our study.
Longer durations of anesthesia and the use of volatile
anesthetics have been previously reported as risk factors
for PONV [22, 23]. The present study showed the risk of
PONV to increase with increasing opioid doses during
surgery; increasing the remifentanil dose by 1000 lg
increased the adjusted OR for nausea by 1.23-fold, while
increasing the fentanyl dose by 100 lg increased the OR
by 1.17-fold within the 0–48 h overall period. Postopera-
tive opioid use is believed to increase PONV in a dose-
dependent manner [24] and was shown in our study to be a
risk factor for nausea. The use of nitrous oxide is also
thought to be a risk factor for PONV [25–27], but this
factor did not have an impact in our study.
The use of 2.5 mg or more neostigmine is a reported risk
factor for PONV [28], but our study revealed no relation-
ship between muscle relaxant antagonist use and PONV,
possibly because sugammadex was frequently used but
neostigmine was not. Although further research is required,
because previous univariate analysis of the effects of sug-
ammadex on PONV showed no relationship, it seems that
sugammadex may not affect PONV.
Apfel et al. [22] state that volatile anesthetics are a strong
risk factor for PONV for up to 2 h after surgery. Stadler et al.
[4] disagree with this conclusion, attributing it to the inclusion
of a high proportion of children and imbalances in surgery
types. Although the present study had a higher proportion of
female patients (64 vs. 53 %) than the study of Stadler et al.
[4], the proportion of child patients was comparable to the
proportion in their study, and our study had no surgery type
imbalances such as those in the study of Apfel et al. [22]. We
found that the use of volatile anesthetics was a risk factor for
nausea, with an adjusted OR of 3.45, only 0–2 h after anes-
thesia. This strengthens the claim of Apfel et al. [22] and
indicates that the impact of volatile anesthetics is very sub-
stantial during the early period 0–2 h after anesthesia.
With regard to perioperatively used opioids, our study
evaluated the intensity of the effects of not only according to
dose but also according to time after anesthesia. Postoper-
ative opioid use, which produces PONV 2 h after anesthesia
and beyond, has been shown to be a significant factor for
delayed PONV 24 h and beyond. In the present study, the
incidence of PONV was relatively high for GYN, RES, and
ABD 24–48 h after anesthesia; postoperative epidural opi-
oids and fentanyl IVPCA were used more frequently after
these types of surgery than the others. We found that
intraoperative remifentanil use had a large impact on PONV
0–2 h after anesthesia. The effects of its use were dimin-
ished 2–24 h after anesthesia and were not observed 24 h
after anesthesia and beyond. Intraoperative fentanyl use had
a comparable impact 0–24 h after anesthesia, but no effects
were noted 24 h after anesthesia and beyond. Although our
study did not closely compare the significance of the effects
of remifentanil and fentanyl by excluding other factors, as in
the study by Rama-Maceiras et al. [29], the adjusted ORs
show that the times of impact and intensities of PONV
differed according to the particular opioid used.
Problematically, the hospital stay of ambulatory surgery
patients may be prolonged by PONV attributable to opioid use
[13–15]. The findings of the present study suggest that
reducing opioid dosage and, particularly, reducing intraoper-
ative fentanyl and postoperative opioid use could be effective
for preventing prolonged hospital stays and delayed PONV.
In overall consideration of the results and given the dif-
ficulty of controlling patient-related factors in the clinic,
controlling anesthesia-related factors appears to be an
effective way of reducing the incidence of PONV. It is
important to avoid using volatile anesthetics, which are a
strong risk factor for nausea during the 2-h period following
anesthesia, and to also reduce the use of opioids, which are a
risk factor for delayed PONV. However, reducing opioid use
has been shown to lead to an increase in anesthetic use [30,
31]; so, using propofol, whose dose Apfel et al. [22] claim is
not proportional to PONV, and using local anesthesia and
NSAIDs as proposed by Shirakami et al. [32] appear to be
viable options for reducing opioid use as much as possible.
No large-scale studies of PONV incidence to support the
use of new antiemetics and no evaluations of the efficacy of
antiemetics used per consensus guidelines for PONV have
been conducted at any Japanese Cancer Center or at any
other institution in Japan. Further investigation will be
required to determine how PONV incidence, as defined in
the present research, can be decreased through prophylaxis
with antiemetics. A risk score must be constructed on the
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basis of the data obtained by this study and evaluated for
effectiveness.
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